GSK’s Nuvalent acquisition brings two lead programs, each addressing different targets for non-small cell lung cancer. The ...
Cancer cells exhibit profound metabolic plasticity that enables them to survive and proliferate under therapeutic pressure. Increasing evidence shows that ...
The tumor microenvironment has emerged as a major regulator of cancer progression across solid tumors, but its influence is particularly pronounced in ...
Is COGT a good stock to buy? We came across a bullish thesis on Cogent Biosciences, Inc. on X.com by @seedy19tron. In this ...
INNMF READ THE FULL INNMF RESEARCH REPORT Amplia Therapeutics (OTCQB: INNMF) is a clinical-stage drug development company ...
Morning Overview on MSN
Disabling NFIL3 via CRISPR kept engineered CAR T-cells from hitting exhaustion, prolonging tumor control in animal models
Researchers at Columbia University’s Sadelain lab and University Hospital Tubingen used CRISPR gene editing to knock out the transcription factor NFIL3 in engineered CAR T cells, and the modified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results